60 Degrees Pharmaceuticals, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K events60 Degrees Pharmaceuticals is a specialty pharmaceutical company commercializing Arakoda, a FDA-approved malaria preventative, and developing tafenoquine-based and Australian Chestnut Extract products.
What they do
60 Degrees Pharmaceuticals markets Arakoda (tafenoquine) for malaria prevention, approved and on the market since late 2019. The company's pipeline includes new tafenoquine-containing products, celgosivir, and botanical extracts from Australian Chestnut trees. It is also conducting clinical development for babesiosis using a tafenoquine regimen.
Revenue drivers
- Arakoda (tafenoquine) — Primary revenue source; a malaria preventative sold in the U.S. since late 2019. Quarterly revenue fluctuated from $100,932 (Jun 2025) to $437,602 (Sep 2025).
- Partnerships and distribution channels — Recently partnered with Runway Health (telehealth) and GoodRx (prescription savings) to expand Arakoda access, potentially driving prescription volume.
Recent performance
Annual revenue grew from $223,208 in 2022 to $1.0M in 2025, though net losses persisted ($-7.4M in 2025). Operating cash flow was negative $-6.8M in 2025. For the quarter ended March 31, 2026, revenue was $162,092, down from $303,385 in the prior quarter. Cash and equivalents totaled $3.3M as of March 31, 2026, with total assets of $6.8M and shareholder equity of $4.8M.
Strategy
Management focuses on expanding Arakoda commercialization through partnerships (e.g., Runway Health, GoodRx) and developing pipeline products. The company is negotiating an exclusive license with Florida State University for purification techniques to extract castanospermine from Australian Chestnut seeds. It submitted an NDIN to the FDA for Australian Chestnut Extract, aiming to market a dietary supplement. Funding is supported by ATM offerings to support working capital, Arakoda commercialization, and babesiosis clinical programs.
Risks
- Limited revenue and recurring losses — Annual revenue of $1.0M is insufficient to cover operating losses (net loss of $7.4M in 2025), raising going-concern risk.
- Dependence on Arakoda — The company relies heavily on a single product, Arakoda, for revenue; any supply, regulatory, or commercial setback could materially affect operations.
- Financing risk — Cash of $3.3M and ongoing negative cash flows require continued capital raises via ATM offerings, which may be dilutive and uncertain.
- Regulatory and clinical uncertainty — Pipeline products, including Australian Chestnut Extract and babesiosis treatment, face FDA regulatory and clinical trial success risks; the NDIN can be objected to by May 25, 2026.
Outlook
Management is focused on growing Arakoda sales through new partnerships and advancing the Australian Chestnut Extract dietary supplement after the NDIN review. The company continues to fund babesiosis clinical development and expects to use ATM proceeds for these priorities. No quantitative guidance is provided, and future performance depends on commercialization execution and additional financing.